← Leaderboards
Adrian Lynn Oblak
Indiana University Indianapolis
$5,075,046
Attributed
$7,245,033
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $14.1M · FY2017–25$20M$15M$10M$5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,785,911 · 7
By mechanism
U54$40,540,878 · 1
R01$2,666,923 · 3
U01$2,217,438 · 1
RF1$1,735,512 · 1
K01$625,160 · 1
Top collaborators
- Bruce T Lamb8 shared
- Michael Sasner7 shared
- Gregory W Carter6 shared
- Gareth R Howell6 shared
- Stacey J Rizzo6 shared
- Paul Richard Territo6 shared
- Timothy I Richardson2 shared
- Andrew D Mesecar1 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Bernardino Ghetti$18,641,814
- Ruben Vidal$8,660,587
- Reuben Kapur$21,257,649
- Michelle L Block$8,185,746
- Alan D. Palkowitz$22,395,390
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposS DiseaseMouse ModelNerve DegenerationAnimal ModelPathologyElderlyIndianaDementiaUniversitiesTau ProteinsTrem2 GenePreventLaboratoriesMutationMissionInnovationNeurodegenerative DisordersNeuropathologyS Disease RiskBrainMolecularCellsEvaluation
Grant awards (18)
IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2025 · AG
Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease$2,217,438
U01 · FY2025 · AG
siRNA-mediated Knockdown of INPP5D to Modulate Microglia Activity for the Treatment of Alzheimer's Disease$792,074
R01 · FY2025 · AG
The Role of Aspergillus versicolor and the Th2 Lung-Brain Axis in Alzheimer's Disease-like Neuropathology$647,352
R01 · FY2025 · AG · contact PI
The Role of Peripheral Immune Cell Trafficking in Ozone-Induced Alzheimer's Disease Neuropathology$566,934
R01 · FY2025 · AG · contact PI
IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2024 · AG
The Role of Aspergillus versicolor and the Th2 Lung-Brain Axis in Alzheimer's Disease-like Neuropathology$660,563
R01 · FY2024 · AG · contact PI
IU/JAX/PITT MODEL-AD Center: Prophylactic Treatment of Long acting GM-CSF (BBT-007) in B6.hAβsaa mice$397,063
U54 · FY2024 · AG
IU/JAX/PITT MODEL-AD Center$9,833,325
U54 · FY2023 · AG
IU/JAX/PITT MODEL-AD Center: Toxicant Exposure Supplement$442,125
U54 · FY2023 · AG
IU/JAX/PITT MODEL-AD Center$9,790,785
U54 · FY2022 · AG
The Role of Peripheral Immune Cell Trafficking in Ozone-Induced Alzheimer's Disease Neuropathology$1,735,512
RF1 · FY2022 · AG · contact PI
In vivo assessment of the role of neurons and glia in tau propagation$125,032
K01 · FY2021 · AG · contact PI
IU/JAX/Pitt MODEL-AD: MAPT-GR$410,930
U54 · FY2020 · AG
In vivo assessment of the role of neurons and glia in tau propagation$125,032
K01 · FY2020 · AG · contact PI
In vivo assessment of the role of neurons and glia in tau propagation$125,032
K01 · FY2019 · AG · contact PI
In vivo assessment of the role of neurons and glia in tau propagation$125,032
K01 · FY2018 · AG · contact PI
In vivo assessment of the role of neurons and glia in tau propagation$125,032
K01 · FY2017 · AG · contact PI